A Phase 3 interventional study of Ustekinumab Dose Based on BSA and Body Weight and Matching Placebo in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Completed at 58 sites in 9 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 25th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen-Cilag Pharma GmbH · Sites in Austria
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 18 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 205 across the 28 interventional studies, 200 across the 15 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
4 of the studies in Colitis, Ulcerative by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT02808780Janssen Biotech, Inc.An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | 2026-12-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with moderately to severely active UC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square \[mg/m\^2\]) or weight-tiered induction dose (milligram per kilogram \[mg/kg\]).
Drug: Ustekinumab Dose Based on BSA and Body Weight
Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
Drug: Ustekinumab Dose Based on BSA and Body Weight · Drug: Matching Placebo
Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
Drug: Ustekinumab Dose Based on BSA and Body Weight · Drug: Matching Placebo
Drug page: UstekinumabStudies of UstekinumabUstekinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
As per BSA and body weight Ustekinumab will be administered SC and IV.
Also known as: STELARA
Placebo will be administered subcutaneously.
Global: Percentage of Participants With Clinical Remission at Induction Week 8
Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Induction Week 8
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AE occurring at or after the initial administration of study intervention.
Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of study intervention.
Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of Participants With AEs Leading to Discontinuation of Study Intervention
Number of participants with AEs leading to discontinuation of study intervention were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of Participants With Adverse Events of Special Interest (AESIs)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active Tuberculosis (TB), or opportunistic infection occurring after the first administration of study intervention.
Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Number of participants with abnormalities in clinical laboratory parameters with increased or decreased hematology parameters such as hemoglobin, anemia, lymphocyte count, platelet count, leukocytosis, white blood cells, were reported. Grades 0-4 were based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.
Time frame: Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Number of participants with abnormalities in clinical laboratory parameters with increased or decreased chemistry parameters such as Alanine Aminotransferase, Aspartate Aminotransferase, Hypoalbuminemia, Alkaline Phosphatase, Blood Bilirubin, Creatinine, Gamma-Glutamyl Transferase, Hyperkalemia, Hypokalemia, Hypernatremia, Hyponatremia were reported. Grades 0-4 were based on NCI-CTCAE version 5.0 where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.
Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) injection-site reactions (Maintenance Period) were reported.
Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Serum Ustekinumab Concentrations
Serum ustekinumab concentrations were reported. PK= pharmacokinetic.
Time frame: Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44
Percentage of Participants With Clinical Response at Induction Week 8
Clinical response was defined as a decrease from induction baseline in the Modified Mayo score by \>=30 percent (%) and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore \>=1 or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Induction Week 8
Percentage of Participants With Symptomatic Remission at Induction Week 8
Symptomatic remission was defined as a Mayo stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal) and a rectal bleeding subscore of 0 (no blood seen), where the stool frequency subscore had not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Induction Week 8
Percentage of Participants With Clinical Remission at Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score
Percentage of participants with clinical remission at Induction Week 8 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50 % of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.
Time frame: Induction Week 8
Percentage of Participants With Endoscopic Improvement at Induction Week 8
Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.
Time frame: Induction Week 8
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Induction Week 8
Histologic-endoscopic mucosal improvement based on Geboes score (GS) was defined as achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system) and endoscopic improvement (Mayo subscore of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Higher score, more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore determined during central review, each subscore graded from 0 (normal) to 3 (severe). Individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher score=more severe disease.
Time frame: Induction Week 8
Percentage of Participants With Clinical Remission at Maintenance Week 44
Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Symptomatic Remission at Maintenance Week 44
Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Clinical Remission at Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score
Percentage of participants with clinical remission at Maintenance Week 44 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50% of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number of stools per 24 hours (0-2 =0, 3-5 =5, 6-8 =10, \>8 =15); nocturnal bowel movement (no =0, yes =10); activity level (no limitation of activity =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Endoscopic Improvement at Maintenance Week 44
Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Clinical Remission at Maintenance Week 44 and Not Receiving Corticosteroids for At Least 90 Days Prior to Maintenance Week 44 Among Participants Who Received Corticosteroids at Induction Week 0
Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8
Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
Time frame: Maintenance Week 44 (Study Week 52)
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44
Histologic-endoscopic mucosal improvement based on Geboes Score: achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system), endoscopic improvement (Mayo sub-score of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; Grade 5, erosions or ulceration. Higher score indicated more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding, endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.
Time frame: Maintenance Week 44 (Study Week 52)
| Milestone | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Started | 112 | 0 | 0 |
| Completed | 109 | 0 | 0 |
| Not completed | 3 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Initiated prohibited medication | 1 | 0 | 0 |
| Milestone | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Started | 0 | 55 | 54 |
| Completed | 0 | 46 | 49 |
| Not completed | 0 | 9 | 5 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 3 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Early escape | 0 | 2 | 1 |
| Withdrew: Initiated prohibited medication | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 1 |
Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of participants | Induction Period: Ustekinumab Intravenous (IV) |
|---|---|
| Global: Percentage of Participants With Clinical Remission at Induction Week 8 | 25 (17.9 to 33.8) |
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AE occurring at or after the initial administration of study intervention.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 59 | 52 | 48 |
Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of study intervention.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) | 6 | 2 | 5 |
Number of participants with AEs leading to discontinuation of study intervention were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Number of Participants With AEs Leading to Discontinuation of Study Intervention | 2 | 3 | 2 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active Tuberculosis (TB), or opportunistic infection occurring after the first administration of study intervention.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Number of Participants With Adverse Events of Special Interest (AESIs) | 0 | 1 | 0 |
Number of participants with abnormalities in clinical laboratory parameters with increased or decreased hematology parameters such as hemoglobin, anemia, lymphocyte count, platelet count, leukocytosis, white blood cells, were reported. Grades 0-4 were based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Hemoglobin Increased Grade 0 | 102 | 54 | 53 |
| Anemia Grade 0 | 57 | 20 | 20 |
| Anemia Grade 1 | 27 | 24 | 25 |
| Anemia Grade 2 | 16 | 7 | 7 |
| Anemia Grade 3 | 2 | 3 | 1 |
| Lymphocyte Count Increased Grade 0 | 100 | 52 | 53 |
| Lymphocyte Count Increased Grade 2 | 1 | 2 | 0 |
| Lymphocyte Count Decreased Grade 0 | 96 | 47 | 44 |
| Lymphocyte Count Decreased Grade 1 | 3 | 4 | 7 |
| Lymphocyte Count Decreased Grade 2 | 1 | 2 | 1 |
| Lymphocyte Count Decreased Grade 3 | 1 | 1 | 1 |
| Platelet Count Decreased Grade 0 | 100 | 54 | 52 |
| Platelet Count Decreased Grade 1 | 0 | 0 | 1 |
| Leukocytosis Grade 0 | 102 | 54 | 53 |
| White Blood Cells Decreased Grade 0 | 94 | 43 | 38 |
| White Blood Cells Decreased Grade 1 | 6 | 11 | 11 |
| White Blood Cells Decreased Grade 2 | 2 | 0 | 4 |
Number of participants with abnormalities in clinical laboratory parameters with increased or decreased chemistry parameters such as Alanine Aminotransferase, Aspartate Aminotransferase, Hypoalbuminemia, Alkaline Phosphatase, Blood Bilirubin, Creatinine, Gamma-Glutamyl Transferase, Hyperkalemia, Hypokalemia, Hypernatremia, Hyponatremia were reported. Grades 0-4 were based on NCI-CTCAE version 5.0 where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Alanine Aminotransferase Increased Grade 0 | 107 | 52 | 47 |
| Alanine Aminotransferase Increased Grade 1 | 0 | 2 | 4 |
| Alanine Aminotransferase Increased Grade 2 | 0 | 0 | 1 |
| Alanine Aminotransferase Increased Grade 3 | 0 | 0 | 1 |
| Aspartate Aminotransferase Increased Grade 0 | 105 | 53 | 47 |
| Aspartate Aminotransferase Increased Grade 1 | 0 | 1 | 5 |
| Aspartate Aminotransferase Increased Grade 2 | 0 | 0 | 1 |
| Hypoalbuminemia Grade 0 | 106 | 54 | 53 |
| Hypoalbuminemia Grade 1 | 1 | 0 | 0 |
| Alkaline Phosphatase Increased Grade 0 | 105 | 48 | 44 |
| Alkaline Phosphatase Increased Grade 1 | 2 | 6 | 8 |
| Alkaline Phosphatase Increased Grade 2 | 0 | 0 | 1 |
| Blood Bilirubin Increased Grade 0 | 102 | 51 | 48 |
| Blood Bilirubin Increased Grade 1 | 0 | 2 | 2 |
| Blood Bilirubin Increased Grade 2 | 5 | 1 | 3 |
| Creatinine Increased Grade 0 | 103 | 51 | 46 |
| Creatinine Increased Grade 1 | 4 | 3 | 6 |
| Creatinine Increased Grade 2 | 0 | 0 | 1 |
| Gamma-Glutamyl Transferase Increased Grade 0 | 107 | 53 | 50 |
| Gamma-Glutamyl Transferase Increased Grade 2 | 0 | 1 | 1 |
| Gamma-Glutamyl Transferase Increased Grade 3 | 0 | 0 | 2 |
| Hyperkalemia Grade 0 | 106 | 50 | 49 |
| Hyperkalemia Grade 1 | 1 | 3 | 3 |
| Hyperkalemia Grade 2 | 0 | 1 | 1 |
| Hypokalemia Grade 0 | 106 | 53 | 52 |
| Hypokalemia Grade 2 | 1 | 1 | 1 |
| Hypernatremia Grade 0 | 107 | 53 | 53 |
| Hypernatremia Grade 1 | 0 | 1 | 0 |
| Hyponatremia Grade 0 | 107 | 54 | 53 |
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) injection-site reactions (Maintenance Period) were reported.
| Participants | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period) | 3 | 0 | 1 |
Serum ustekinumab concentrations were reported. PK= pharmacokinetic.
| micrograms per milliliter | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|---|
| Week I-0, Pre-infusion | 0.020 ± 0.1194 | — | — |
| Week I-0, 1-hour post infusion | 115.269 ± 30.4642 | — | — |
| Week I-2 | 29.157 ± 8.9948 | — | — |
| Week I-4 | 15.356 ± 6.9475 | — | — |
| Week I-8 | 5.018 ± 3.6498 | — | — |
| Week M-4 | — | 6.065 ± 3.7782 | 7.405 ± 3.9628 |
| Week M-8 | — | 2.401 ± 2.3224 | 3.163 ± 2.5936 |
| Week M-12 | — | 0.972 ± 1.1688 | 6.697 ± 3.4813 |
| Week M-16 | — | 5.138 ± 2.7522 | 3.125 ± 2.2043 |
| Week M-24 | — | 0.935 ± 0.9591 | 3.544 ± 2.3097 |
| Week M-32 | — | 2.205 ± 2.0274 | 3.650 ± 2.3885 |
| Week M-36 | — | 1.041 ± 1.3616 | 7.626 ± 2.6618 |
| Week M-44 | — | 2.439 ± 2.3689 | 7.603 ± 2.8930 |
Clinical response was defined as a decrease from induction baseline in the Modified Mayo score by \>=30 percent (%) and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore \>=1 or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of Participants | Induction Period: Ustekinumab Intravenous (IV) |
|---|---|
| Percentage of Participants With Clinical Response at Induction Week 8 | 67.0 (57.8 to 75.0) |
Symptomatic remission was defined as a Mayo stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal) and a rectal bleeding subscore of 0 (no blood seen), where the stool frequency subscore had not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of Participants | Induction Period: Ustekinumab Intravenous (IV) |
|---|---|
| Percentage of Participants With Symptomatic Remission at Induction Week 8 | 48.2 (39.2 to 57.4) |
Percentage of participants with clinical remission at Induction Week 8 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50 % of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.
| Percentage of participants | Induction Period: Ustekinumab Intravenous (IV) |
|---|---|
| Percentage of Participants With Clinical Remission at Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score | 38.4 (29.9 to 47.6) |
Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.
| Percentage of participants | Induction Period: Ustekinumab Intravenous (IV) |
|---|---|
| Percentage of Participants With Endoscopic Improvement at Induction Week 8 | 30.4 (22.6 to 39.4) |
Histologic-endoscopic mucosal improvement based on Geboes score (GS) was defined as achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system) and endoscopic improvement (Mayo subscore of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Higher score, more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore determined during central review, each subscore graded from 0 (normal) to 3 (severe). Individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher score=more severe disease.
| Percentage of participants | Induction Period: Ustekinumab Intravenous (IV) |
|---|---|
| Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Induction Week 8 | 19.6 (13.3 to 28.0) |
Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of Participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Clinical Remission at Maintenance Week 44 | 32.5 (20.1 to 48.0) | 48.7 (33.9 to 63.8) |
Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of Participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Symptomatic Remission at Maintenance Week 44 | 57.5 (42.2 to 71.5) | 74.4 (58.9 to 85.4) |
Percentage of participants with clinical remission at Maintenance Week 44 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50% of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number of stools per 24 hours (0-2 =0, 3-5 =5, 6-8 =10, \>8 =15); nocturnal bowel movement (no =0, yes =10); activity level (no limitation of activity =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.
| Percentage of Participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Clinical Remission at Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score | 57.5 (42.2 to 71.5) | 71.8 (56.2 to 83.5) |
Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.
| Percentage of Participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Endoscopic Improvement at Maintenance Week 44 | 32.5 (20.1 to 48.0) | 48.7 (33.9 to 63.8) |
Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44 | 32.5 (20.1 to 48.0) | 48.7 (33.9 to 63.8) |
Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Clinical Remission at Maintenance Week 44 and Not Receiving Corticosteroids for At Least 90 Days Prior to Maintenance Week 44 Among Participants Who Received Corticosteroids at Induction Week 0 | 41.2 (21.6 to 64.0) | 56.3 (33.2 to 76.9) |
Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.
| Percentage of participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8 | 63.6 (35.4 to 84.8) | 56.3 (33.2 to 76.9) |
Histologic-endoscopic mucosal improvement based on Geboes Score: achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system), endoscopic improvement (Mayo sub-score of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; Grade 5, erosions or ulceration. Higher score indicated more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding, endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.
| Percentage of participants | Maintenance Period: Ustekinumab SC q12w | Maintenance Period: Ustekinumab SC q8w |
|---|---|---|
| Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44 | 27.5 (16.1 to 42.8) | 46.2 (31.6 to 61.4) |
Collected over All-cause mortality: From screening (-6 weeks) up to Week I-8 (Induction Period); from Week M-0 (Study Week 8) up to Week M-44(Study Week 52) (Maintenance period); Serious and other AEs: From Week I-0 up to Week I-8 (Induction Period); from Week M-0 (Study Week 8) up to Week M-44 (Study Week 52) (Maintenance period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Period: Ustekinumab Intravenous (IV) | 0/112 (0%) | 6/112 (5.4%) | 42/112 (37.5%) |
| Maintenance Period: Ustekinumab SC Every 12 Weeks (q12w) | 0/55 (0%) | 2/55 (3.6%) | 46/55 (83.6%) |
| Maintenance Period: Ustekinumab SC Every 8 Weeks (q8w) | 0/54 (0%) | 5/54 (9.3%) | 40/54 (74.1%) |
| Event | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC Every 12 Weeks (q12w) | Maintenance Period: Ustekinumab SC Every 8 Weeks (q8w) |
|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 2/112 | 0/55 | 2/54 |
| AnaemiaBlood and lymphatic system disorders | 2/112 | 0/55 | 1/54 |
| SalmonellosisInfections and infestations | 0/112 | 0/55 | 1/54 |
| Suicidal IdeationPsychiatric disorders | 0/112 | 0/55 | 1/54 |
| MalnutritionMetabolism and nutrition disorders | 0/112 | 1/55 | 0/54 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/112 | 1/55 | 0/54 |
| Subcutaneous AbscessInfections and infestations | 1/112 | 0/55 | 0/54 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 1/112 | 0/55 | 0/54 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 0/112 | 0/55 | 0/54 |
| Acute Kidney InjuryRenal and urinary disorders | 0/112 | 0/55 | 0/54 |
| Event | Induction Period: Ustekinumab Intravenous (IV) | Maintenance Period: Ustekinumab SC Every 12 Weeks (q12w) | Maintenance Period: Ustekinumab SC Every 8 Weeks (q8w) |
|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 4/112 | 21/55 | 12/54 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/112 | 13/55 | 14/54 |
| NasopharyngitisInfections and infestations | 2/112 | 7/55 | 11/54 |
| AnaemiaBlood and lymphatic system disorders | 11/112 | 5/55 | 8/54 |
| HeadacheNervous system disorders | 5/112 | 7/55 | 3/54 |
| Covid-19Infections and infestations | 7/112 | 5/55 | 2/54 |
| NauseaGastrointestinal disorders | 2/112 | 1/55 | 4/54 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 2/112 | 4/55 | 0/54 |
| HaematocheziaGastrointestinal disorders | 1/112 | 4/55 | 2/54 |
| Respiratory Tract InfectionInfections and infestations | 0/112 | 4/55 | 2/54 |
| Age, Continuous(years) | Ustekinumab IV (Induction) |
|---|---|
| Mean | 13.2 ± 3.09 |
| Age, Customized(Participants) | Ustekinumab IV (Induction) |
|---|---|
| 2-<12 years | 30 |
| 12-<18 years | 82 |
| Sex: Female, Male(Participants) | Ustekinumab IV (Induction) |
|---|---|
| Female | 61 |
| Male | 51 |
| Ethnicity (NIH/OMB)(Participants) | Ustekinumab IV (Induction) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 108 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Ustekinumab IV (Induction) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 13 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 94 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(Participants) | Ustekinumab IV (Induction) |
|---|---|
| BELGIUM | 13 |
| GERMANY | 8 |
| HUNGARY | 11 |
| ISRAEL | 3 |
| JAPAN | 10 |
| POLAND | 59 |
| UNITED KINGDOM | 4 |
| UNITED STATES | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Mar 2021 to primary completion in May 2025, 49 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion. A results delay was requested in May 2026.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 49 months is close to that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ustekinumab
Janssen Research & Development, LLC →